CCA
ABMD

Column Capital Advisors’s Abiomed Inc ABMD Stock Holding History

Column Capital Advisors’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-453
Closed -$77K – 812
2019
Q4 		$77K Buy
+453
New +$84K 0.04% 177

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Column Capital Advisors's ABMD Position: Q1 2020 in Review

Column Capital Advisors sold out of Abiomed Inc (ABMD) in Q1 2020, closing a stake of 453 shares — an estimated $77K sold.

Column Capital Advisors first reported a position in ABMD in Q4 2019 and held it in 1 quarter. The position peaked at $77K in Q4 2019. 412 funds tracked by Wall St. Rank hold ABMD as of Q1 2020.

  • Column Capital Advisors reported no remaining Abiomed Inc position as of Q1 2020 after selling out during the quarter.
  • Column Capital Advisors sold 453 Abiomed Inc shares in Q1 2020, an estimated $77K.
  • Column Capital Advisors first reported a position in Abiomed Inc in Q4 2019 and held it in 1 quarter.
  • Column Capital Advisors's Abiomed Inc position peaked at $77K in Q4 2019.
  • 412 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2020.

Based on Column Capital Advisors's 13F filing for Q1 2020, filed 11 May 2020.